Valuation: NEOVACS

Market Cap 4.09K 4.7K 3.81K 3.49K 6.6K 449K 6.7K 44.86K 17.61K 224K 17.67K 17.28K 750K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -231K -187K -172K -324K -22.07M -329K -2.21M -865K -10.99M -868K -849K -36.85M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 134K
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.45%+1.05%+59.43%+103.27% 27.82B
Weighted average by Cap. -1.60%+2.03%+76.87%+128.10%

Financials

2023 2024
Net sales 533K 614K 496K 456K 861K 58.58M 874K 5.85M 2.3M 29.16M 2.3M 2.25M 97.78M 434K 499K 404K 371K 700K 47.65M 711K 4.76M 1.87M 23.72M 1.87M 1.83M 79.55M
Net income -8.74M -10.06M -8.14M -7.47M -14.11M -960M -14.33M -95.93M -37.65M -478M -37.77M -36.94M -1.6B -32.91M -37.86M -30.64M -28.13M -53.12M -3.61B -53.94M -361M -142M -1.8B -142M -139M -6.03B
Net Debt -237K -272K -220K -202K -382K -25.97M -388K -2.59M -1.02M -12.93M -1.02M -999K -43.35M -205K -236K -191K -175K -331K -22.52M -336K -2.25M -883K -11.21M -886K -867K -37.59M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-